Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Fulgent Genetics, Inc. FLGT
$35.01
+$0.63 (1.80%)
На 18:01, 12 мая 2023
+28.53%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
1020830244.00000000
-
week52high
65.17
-
week52low
28.27
-
Revenue
618968000
-
P/E TTM
7
-
Beta
1.55155700
-
EPS
4.50000000
-
Last Dividend
0.00000000
-
Next Earnings Date
05 мая 2023 г. в 12:30
Описание компании
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Credit Suisse | Outperform | 25 авг 2022 г. | |
| Piper Sandler | Overweight | Overweight | 16 мая 2022 г. |
| Oppenheimer | Outperform | Outperform | 25 янв 2022 г. |
| Credit Suisse | Underperform | Underperform | 10 авг 2021 г. |
| Piper Sandler | Overweight | Overweight | 05 мар 2021 г. |
| Piper Sandler | Overweight | Overweight | 14 ноя 2022 г. |
| Credit Suisse | Outperform | Outperform | 14 ноя 2022 г. |
| Raymond James | Outperform | 18 ноя 2022 г. | |
| Piper Sandler | Neutral | Overweight | 08 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Xie Jian | D | 429450 | 624 | 01 февр 2023 г. |
| Gao Hanlin | D | 906495 | 90 | 30 янв 2023 г. |
| GROVES REGINA E | A | 10000 | 10000 | 03 янв 2023 г. |
| GROVES REGINA E | A | 4000 | 4000 | 03 янв 2023 г. |
| KIM PAUL | D | 223403 | 653 | 02 дек 2022 г. |
| Xie Jian | D | 430074 | 685 | 30 ноя 2022 г. |
| Xie Jian | D | 430759 | 1306 | 16 ноя 2022 г. |
| Gao Hanlin | D | 906585 | 342 | 16 ноя 2022 г. |
| KIM PAUL | D | 224056 | 490 | 16 ноя 2022 г. |
| KIM PAUL | D | 224546 | 1306 | 16 ноя 2022 г. |
Новостная лента
Is Fulgent Genetics (FLGT) Stock Outpacing Its Medical Peers This Year?
Zacks Investment Research
08 мая 2023 г. в 11:26
Here is how Fulgent Genetics, Inc. (FLGT) and Masimo (MASI) have performed compared to their sector so far this year.
Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
05 мая 2023 г. в 09:54
Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to earnings of $4.93 per share a year ago.
7 Stocks to Buy to Bag Big-Time Returns in Q2
InvestorPlace
16 апр 2023 г. в 14:01
If you're the type that runs toward danger, these stocks to buy may be right for you. To facilitate mobility, the enterprises on this list feature a market capitalization between $500 million to $2 billion.
Are Medical Stocks Lagging Fulgent Genetics (FLGT) This Year?
Zacks Investment Research
12 апр 2023 г. в 11:24
Here is how Fulgent Genetics, Inc. (FLGT) and Harrow Health (HROW) have performed compared to their sector so far this year.
Is Fulgent Genetics (FLGT) Outperforming Other Medical Stocks This Year?
Zacks Investment Research
09 мар 2023 г. в 11:25
Here is how Fulgent Genetics, Inc. (FLGT) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.